UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
Form 6-K
REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR
15d-16
UNDER THE SECURITIES EXCHANGE ACT OF 1934
For the
month of March 2020
Commission
File Number 001-15170
GlaxoSmithKline plc
(Translation
of registrant's name into English)
980 Great West Road, Brentford, Middlesex, TW8 9GS
(Address
of principal executive office)
Indicate
by check mark whether the registrant files or will file annual
reports under cover of Form 20-F or Form 40-F.
Form
20-F . . . .X. . . . Form 40-F . . . . . . . .
Indicate
by check mark if the registrant is submitting the Form 6-K in paper
as permitted by Regulation S-T Rule 101(b)(1): ____
Indicate
by check mark if the registrant is submitting the Form 6-K in paper
as permitted by Regulation S-T Rule 101(b)(7): ____
Issued: 20 March 2020, London UK
GSK appoints Charles Bancroft to the Board as a Non-Executive
Director
GlaxoSmithKline plc (LSE/NYSE: GSK) today announced that Charles
Bancroft will join the Board of the Company as a Non-Executive
Director on 1 May 2020.
Charlie has recently retired from a successful career at Bristol
Myers Squibb (BMS) where he held a number of leadership roles in
commercial, strategy and finance. Beginning his career at BMS in
1984, he held positions of increasing responsibility within the
finance organisation and had commercial operational responsibility
for Latin America, Middle East, Africa, Canada, Japan and several
Pacific Rim countries. He was appointed Chief Financial Officer in
2010, Chief Financial Officer and Executive Vice President, Global
Business Operations in 2016 and Executive Vice President and Head
of Integration and Strategy & Business Development in 2019.
Charlie successfully steered BMS through a period of strategic
transformation, including the recent $74bn acquisition of
Celgene.
Charlie served as a member of the Board of Colgate-Palmolive
Company from 2017 until March 2020.
On
joining the Board Charlie will become a member of the Audit &
Risk Committee. He will succeed Judy Lewent as Chair of this
Committee following approval of GSK's 2020 Annual Report in Q1 of
2021.
Commenting on the appointment, Sir Jonathan Symonds, Chairman of
GSK said: "I am delighted Charlie is joining the GSK Board and has
agreed to succeed Judy in 2021 as Chair of our Audit & Risk
Committee. He brings a wealth of financial and management
experience in global biopharma which will be invaluable to the
Board in the coming years as it oversees the delivery of GSK's
strategy, including the separation of the Group and the creation of
two outstanding new companies."
Notes
1.
|
The
appointment of Charles Bancroft was made by the Board on the
recommendation of the Nominations Committee.
|
2.
|
The
Board determined that Mr Bancroft is an independent Non-Executive
Director on appointment in accordance with the UK Corporate
Governance Code (the Code). He has also been designated as having
recent and relevant financial experience for the purposes of the
Code and as an audit committee financial expert as defined in rules
promulgated under the Sarbanes-Oxley Act of 2002.
|
3.
|
He will
receive the standard basic fee for a Non-Executive Director of
£95,000 per annum and when he succeeds Ms Lewent as Chair of
the Audit & Risk Committee, he will receive the supplemental
fee of £80,000 per annum. He will be required to invest at
least 25% of his fees in GSK shares that should be held until he
retires from the Board.
|
4.
|
Membership
of other Committees will be determined in due course.
|
5.
|
Mr
Bancroft does not have a service contract. He has a letter of
appointment which may be viewed by contacting the Company Secretary
at the Company's registered office.
|
6.
|
There
are no additional details to disclose in respect of Mr Bancroft's
appointment under Listing Rule 9.6.13R.
|
7.
|
From 1
May 2020 the Board of GSK will comprise:
|
|
Sir
Jonathan Symonds
Emma
Walmsley
Iain
Mackay
Dr Hal
Barron
Vindi
Banga
Charles
Bancroft
Dr
Vivienne
Cox
Lynn
Elsenhans
Dr
Jesse Goodman
Dr
Laurie Glimcher
Judy
Lewent
Urs
Rohner
|
Non-Executive
Chairman
Chief
Executive Officer
Chief
Financial Officer
Chief
Scientific Officer and President, R&D
Senior
Independent Non-Executive Director
Independent
Non-Executive Director
Independent
Non-Executive Director
Independent
Non-Executive Director
Independent
Non-Executive Director
Independent
Non-Executive Director
Independent
Non-Executive Director
Independent
Non-Executive Director
|
About GSK
GSK is a science-led global healthcare company with a special
purpose: to help people do more, feel better, live longer. For
further information please visit www.gsk.com/about-us.
GSK enquiries:
|
|
|
|
UK
Media enquiries:
|
Simon
Steel
|
+44 (0)
20 8047 5502
|
(London)
|
|
Mary
Hinks-Edwards
|
+44 (0)
20 8047 5502
|
(London)
|
|
|
|
|
US
Media enquiries:
|
Kathleen
Quinn
|
+1 202
603 5003
|
(Washington
DC)
|
|
|
|
|
Analyst/Investor
enquiries:
|
Sarah
Elton-Farr
|
+44 (0)
208 047 5194
|
(London)
|
|
Danielle
Smith
|
+44 (0)
20 8047 7562
|
(London)
|
|
James
Dodwell
|
+44 (0)
20 8047 2406
|
(London)
|
Cautionary
statement regarding forward-looking statements
GSK cautions
investors that any forward-looking statements or projections made
by GSK, including those made in this announcement, are subject to
risks and uncertainties that may cause actual results to differ
materially from those projected. Such factors include, but are not
limited to, those described under Item 3.D 'Principal risks and
uncertainties' in the company's Annual Report on Form 20-F for
2019.
Registered in England & Wales:
No.
3888792
Registered
Office:
980 Great West
Road
Brentford,
Middlesex
TW8
9GS
SIGNATURES
Pursuant
to the requirements of the Securities Exchange Act of 1934, the
registrant has duly caused this report to be signed on its behalf
by the undersigned, thereunto duly authorised.
|
GlaxoSmithKline plc
|
|
(Registrant)
|
|
|
Date: March
20, 2020
|
|
|
|
|
By:/s/ VICTORIA
WHYTE
--------------------------
|
|
|
|
Victoria Whyte
|
|
Authorised
Signatory for and on
|
|
behalf
of GlaxoSmithKline plc
|